Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial

Trial Profile

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axitinib (Primary) ; Bosutinib (Primary) ; Cobimetinib (Primary) ; Crizotinib (Primary) ; Dasatinib (Primary) ; Erlotinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Olaparib (Primary) ; Palbociclib (Primary) ; Pertuzumab (Primary) ; Sunitinib (Primary) ; Temsirolimus (Primary) ; Trastuzumab (Primary) ; Vemurafenib (Primary) ; Vismodegib (Primary)
  • Indications Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Therapeutic Use
  • Acronyms CAPTUR
  • Most Recent Events

    • 05 Jun 2018 Results of phase II basket precision medicine trial (CAPTUR) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 15 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 09 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top